SAVE THE DATE: 🚀 Immunotherapy Beyond Checkpoint Inhibitors

SAVE THE DATE

🚀 Immunotherapy Beyond Checkpoint Inhibitors

Bispecific Antibodies & Advanced Therapy Medicinal Products (ATMPs) in Solid Tumours

A joint BOPA & Pan-UK ATMP Pharmacy Working Group Study Day

📅 Tuesday 17 November 2026
🕙 10:00–16:00
📍 Wellcome Collection, London (Teams access being considered)

The future of cancer immunotherapy is already here…

Checkpoint inhibitors transformed solid tumour oncology practice. The next wave of innovation is already changing how we deliver cancer care.

Bispecific antibodies, tumour infiltrating lymphocytes (TILs), cancer vaccines, oncolytic viruses and other Advanced Therapy Medicinal Products (ATMPs) are rapidly moving into solid tumour treatment, bringing exciting opportunities—but also significant new challenges for pharmacy.

Whether your organisation is already delivering these therapies or preparing for future implementation, pharmacy teams will be central to ensuring they are introduced safely, effectively and sustainably.

Join colleagues from across the UK to explore the clinical evidence, practical considerations and service developments that will shape the future of oncology pharmacy.

Why attend?

✔ Understand the emerging immunotherapy landscape beyond checkpoint inhibitors

✔ Gain practical knowledge of bispecific antibodies and ATMP implementation

✔ Learn how specialist centres are preparing for TIL therapy

✔ Explore governance, legislation and commissioning requirements

✔ Discuss toxicity management and supportive care with national experts

✔ Network with colleagues leading implementation across the UK

Who should attend?

This event is designed for:

🟢 Senior Oncology Pharmacists

🟢 Senior Pharmacy Technicians

🟢 Pharmacy Managers

🟢 Cancer Services Pharmacy Teams

🟢 Pharmacy professionals supporting ATMP implementation

No prior experience with ATMPs or bispecific antibodies is required—this event is specifically designed to help prepare solid tumour pharmacy teams for the next generation of cancer treatments.

Places are limited

Approximately 50 in-person places are available.

💻 Virtual attendance via Microsoft Teams may also be available.

Register your interest

Please express your interest here

Immunotherapy Beyond Checkpoint Inhibitors – Fill in form

Registration details will follow

We look forward to welcoming you

Join us as we explore how pharmacy can lead the safe implementation of the next generation of cancer immunotherapies.

Alice Tew (co-chair BOPA Immunotherapy Specialist Interest Group)

Jessica Pealing (PanUK ATMP representative within BOPA)